Please assess the completion status of the following clinical trial:

Trial Title: Post-operative or Early Salvage XRT and ADT for High Risk PCa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of prostate cancer~  * Clinical stage cT1-2-3a, N0, M0 disease pre-operatively~ * Pre-operative PSA ≤ 5 x upper limit of normal~* Presenting the following conditions after radical prostatectomy:~  * Gleason sum 5-10~ * Pathologic stage pT2R1 (positive surgical margins with at least a tumor trans-section \> 2 mm) or pT3a-b (irrespective of margin status)~ * Negative lymph node (LN) status (pN0) by LN sampling or LN dissection~    * Unknown pathological LN status is not allowed, except for disease classified as cT ≤ cT1c with baseline PSA ≤ 10 ng/mL, Gleason score \< 7, and ≥ 12 positive core biopsies \< 50%~ * Undetectable post-operative PSA within 3 months of surgery~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* WBC ≥ 3 x 10\^9/L~* Hemoglobin ≥ 110 g/L~* Platelet count ≥ 100 x 10\^9/L~* No other malignancy except adequately treated basal cell carcinoma of the skin or other malignancy from which the patient has been disease free for at least 5 years~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 5 years since prior chemotherapy~* No prior pelvic irradiation~* No prior bilateral orchiectomy~* No prior hormonal treatment except neoadjuvant treatment lasting ≤ 3 months~* No other concurrent anticancer agent or modality

- Gender: MALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
- Arm II (Type: EXPERIMENTAL): Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).